These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 19261604)
1. Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation. Zhou X; Agazie YM J Biol Chem; 2009 May; 284(18):12226-34. PubMed ID: 19261604 [TBL] [Abstract][Full Text] [Related]
2. A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2). Hartman Z; Geldenhuys WJ; Agazie YM J Biol Chem; 2020 Mar; 295(11):3563-3575. PubMed ID: 32024694 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells. Zhou XD; Agazie YM Cell Death Differ; 2008 Jun; 15(6):988-96. PubMed ID: 18421299 [TBL] [Abstract][Full Text] [Related]
4. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Aceto N; Sausgruber N; Brinkhaus H; Gaidatzis D; Martiny-Baron G; Mazzarol G; Confalonieri S; Quarto M; Hu G; Balwierz PJ; Pachkov M; Elledge SJ; van Nimwegen E; Stadler MB; Bentires-Alj M Nat Med; 2012 Mar; 18(4):529-37. PubMed ID: 22388088 [TBL] [Abstract][Full Text] [Related]
5. The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3. Agazie YM; Movilla N; Ischenko I; Hayman MJ Oncogene; 2003 Oct; 22(44):6909-18. PubMed ID: 14534538 [TBL] [Abstract][Full Text] [Related]
6. A novel role for Gab1 and SHP2 in epidermal growth factor-induced Ras activation. Montagner A; Yart A; Dance M; Perret B; Salles JP; Raynal P J Biol Chem; 2005 Feb; 280(7):5350-60. PubMed ID: 15574420 [TBL] [Abstract][Full Text] [Related]
7. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. Agazie YM; Hayman MJ Mol Cell Biol; 2003 Nov; 23(21):7875-86. PubMed ID: 14560030 [TBL] [Abstract][Full Text] [Related]
8. Src homology phosphotyrosyl phosphatase 2 mediates cisplatin-related drug resistance by inhibiting apoptosis and activating the Ras/PI3K/Akt1/survivin pathway in lung cancer cells. Tang C; Luo H; Luo D; Yang H; Zhou X Oncol Rep; 2018 Feb; 39(2):611-618. PubMed ID: 29207183 [TBL] [Abstract][Full Text] [Related]
9. Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants. Fan YX; Wong L; Marino MP; Ou W; Shen Y; Wu WJ; Wong KK; Reiser J; Johnson GR J Biol Chem; 2013 Jun; 288(23):16895-16904. PubMed ID: 23612964 [TBL] [Abstract][Full Text] [Related]
10. SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis. Zhou X; Coad J; Ducatman B; Agazie YM Histopathology; 2008 Oct; 53(4):389-402. PubMed ID: 18643929 [TBL] [Abstract][Full Text] [Related]
11. Altered glucose homeostasis in mice with liver-specific deletion of Src homology phosphatase 2. Matsuo K; Delibegovic M; Matsuo I; Nagata N; Liu S; Bettaieb A; Xi Y; Araki K; Yang W; Kahn BB; Neel BG; Haj FG J Biol Chem; 2010 Dec; 285(51):39750-8. PubMed ID: 20841350 [TBL] [Abstract][Full Text] [Related]
12. HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling. Hartman Z; Zhao H; Agazie YM Oncogene; 2013 Aug; 32(35):4169-80. PubMed ID: 23027125 [TBL] [Abstract][Full Text] [Related]
13. Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis. Zhao H; Martin E; Matalkah F; Shah N; Ivanov A; Ruppert JM; Lockman PR; Agazie YM Oncogene; 2019 Mar; 38(13):2275-2290. PubMed ID: 30467378 [TBL] [Abstract][Full Text] [Related]
14. A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth. Patel Y; Shah N; Lee JS; Markoutsa E; Jie C; Liu S; Botbyl R; Reisman D; Xu P; Chen H Oncotarget; 2016 Apr; 7(14):18295-308. PubMed ID: 26918448 [TBL] [Abstract][Full Text] [Related]
15. Receptor-specific regulation of phosphatidylinositol 3'-kinase activation by the protein tyrosine phosphatase Shp2. Zhang SQ; Tsiaras WG; Araki T; Wen G; Minichiello L; Klein R; Neel BG Mol Cell Biol; 2002 Jun; 22(12):4062-72. PubMed ID: 12024020 [TBL] [Abstract][Full Text] [Related]
16. Shp2 signaling suppresses senescence in PyMT-induced mammary gland cancer in mice. Lan L; Holland JD; Qi J; Grosskopf S; Rademann J; Vogel R; Györffy B; Wulf-Goldenberg A; Birchmeier W EMBO J; 2015 Jun; 34(11):1493-508. PubMed ID: 25736378 [TBL] [Abstract][Full Text] [Related]
17. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer. Matalkah F; Martin E; Zhao H; Agazie YM Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598 [TBL] [Abstract][Full Text] [Related]
18. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification. Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301 [TBL] [Abstract][Full Text] [Related]
19. Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET. Liu JJ; Li Y; Chen WS; Liang Y; Wang G; Zong M; Kaneko K; Xu R; Karin M; Feng GS J Hepatol; 2018 Jul; 69(1):79-88. PubMed ID: 29505847 [TBL] [Abstract][Full Text] [Related]
20. Modulation of alpha-catenin Tyr phosphorylation by SHP2 positively effects cell transformation induced by the constitutively active FGFR3. Burks J; Agazie YM Oncogene; 2006 Nov; 25(54):7166-79. PubMed ID: 16767162 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]